ORIC Pharmaceuticals Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
-4.9%projected annual EPS growth
Analyst Coverage
13analysts covering
FY EPS (est.)
-$1.49next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 10 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Cash, Cash Equivalents, and Short-Term Investments Quarterly290.2MTarget: Sufficient to fund operations into 2H 2028
Quarterly Net Loss Quarterly-35.8MTarget: Manageable cash burn aligned with clinical milestones
Himalayas-1 Phase 3 Trial Enrollment Annually
Watch Items
- Rinzimetostat (ORIC-944) Himalayas-1 Phase 3 Trial InitiationTrigger: Initiation of the first global Phase 3 registrational trial in mCRPCAction: Monitor clinical trial registry updates and company press releases for official study start in 1H 2026.
- Enozertinib (ORIC-114) Clinical Data ReadoutsTrigger: Release of 1L EGFR exon 20 monotherapy and combination data with SC amivantamab, and 1L EGFR PACC monotherapy dataAction: Evaluate efficacy (systemic and intracranial activity) and safety profiles against competitor benchmarks in 2H 2026.
- Rinzimetostat (ORIC-944) Program UpdateTrigger: Program update in mCRPCAction: Review clinical progress and combination dose optimization data in 2H 2026.
Research as of 19 Jun 2026